Skip to main content

Advertisement

SpringerLink
Log in

Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The development of chemoprevention strategies against prostate cancer would have the greatest overall impact both medically and economically against prostate cancer. Estrogens are required for prostate carcinogenesis. Estrogenic stimulation through estrogen receptor α in a milieu of decreasing androgens contributes significantly to the genesis of benign prostatic hyperplasia, prostate dysplasia, and prostate cancer. The ability of antiestrogens and selective estrogen receptor modulators (SERMs) to delay and to suppress prostate carcinogenesis is supported by preclinical, clinical, and epidemiological studies. SERMs have many features that make them attractive candidates for prostate cancer chemoprevention including their favorable safety profile and efficacy in preclinical prostate cancer models. The true clinical benefits of SERMs for chemoprevention to prevent prostate cancer, however, should continue to be investigated through human clinical trials. A phase IIb/III human clinical trial is currently evaluating safety and efficacy of toremifene, a SERM, in men who have high-grade prostatic intraepithelial neoplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arai Y, Chen CY, Nishizuka Y (1978) Cancer development in male reproductive tract in rats given diethylstilbestrol at neonatal age. Gann 69:861–862

    PubMed  Google Scholar 

  2. Aronica SM, Katzenellenbogen BS (1993) Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743–752

    CAS  PubMed  Google Scholar 

  3. Black LJ, Goode RL (1980) Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci 26:1453–1458

    Article  CAS  PubMed  Google Scholar 

  4. Blanchere M, Berthaut I, Portois MC, Mestayer C, Mowszowicz I (1998) Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J Steroid Biochem Mol Biol 66:319–326

    Article  CAS  PubMed  Google Scholar 

  5. Bodker A, Bruun J, Balslev E, Iversen HG, Meyhoff HH, Andersson KE (1999) Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia. Scand J Urol Nephrol 33:237–242

    Article  CAS  PubMed  Google Scholar 

  6. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155:641–647

    CAS  PubMed  Google Scholar 

  7. Brolin J, Skoog L, Ekman P (1992) Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20:281–295

    CAS  PubMed  Google Scholar 

  8. Bruning P, Bonfrer J, Hart A (1988) Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497–499

    CAS  PubMed  Google Scholar 

  9. Buelke-Sam J, Bryant HU, Francis PC (1998) The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 12:217–221

    Article  CAS  PubMed  Google Scholar 

  10. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, Calabro M, Carruba G (1995) Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136:2309–2319

    CAS  PubMed  Google Scholar 

  11. Castle EP, Thrasher JB (2002) The role of soy phytoestrogens in prostate cancer. Urol Clin North Am 29:71–81

    PubMed  Google Scholar 

  12. Chang WY, Prins GS (1999) Estrogen receptor-beta: implications for the prostate gland. Prostate 40:115–124

    Article  CAS  PubMed  Google Scholar 

  13. Cheng E, Lee C, Grayhack J (1993) Endocrinology of the prostate. In: Lepor H, Lawson R (eds) Prostate diseases. Saunders, Philadelphia, pp 57–71

  14. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS (1997) Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138:4613–4621

    CAS  PubMed  Google Scholar 

  15. Denis L, Morton MS, Griffiths K (1999) Diet and its preventive role in prostatic disease. Eur Urol 35:377–387

    Article  CAS  PubMed  Google Scholar 

  16. Ehara H, Koji T, Deguchi T, Yoshii A, Nakano M, Nakane PK, Kawada Y (1995) Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry. Prostate 27:304–313

    CAS  PubMed  Google Scholar 

  17. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA (1997) Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258–4265

    CAS  PubMed  Google Scholar 

  18. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096–4102

    CAS  PubMed  Google Scholar 

  19. Gingrich JR, Barrios RJ, Kattan MJ, Nahm HS, Finegold MJ, Greenberg NM (1997) Androgen independent prostate cancer progression in the TRAMP model. Cancer Res 57:4687–4691

    CAS  PubMed  Google Scholar 

  20. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439–3443

    CAS  PubMed  Google Scholar 

  21. Griffiths K, Cockett A, Coffey D, Krieg M, Lee C, McKeehan W, Neal D, Partin A, DiSant'Agnese A, Schalken J (1998) Regulation of prostate growth. 4th International Consultation on BPH, Paris, pp 83–128

  22. Habenicht UF, el Etreby MF (1988) The periurethral zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus. Prostate 13:305–316

    CAS  PubMed  Google Scholar 

  23. Hanstein B, Liu H, Yancisin MC, Brown M (1999) Functional analysis of a novel estrogen receptor-beta isoform. Mol Endocrinol 13:129–137

    CAS  PubMed  Google Scholar 

  24. Hard GC, Iatropoulous MJ, Jordan K (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53:4534–4541

    CAS  PubMed  Google Scholar 

  25. Ho S-M, Lee K-F, Lane K (1997) Neoplastic transformation of the prostate. In: Naz R (ed) Prostate basic and clinical aspects. CRC, New York, pp 74–114

  26. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167–1177

    CAS  PubMed  Google Scholar 

  27. Kelloff GJ, Boone CW, Malone WF, Steele VE, Doody LA (1992) Introductory remarks: Development of chemopreventive agents for prostate cancer. J Cell Biochem Suppl 16H:1–8

    CAS  Google Scholar 

  28. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC (1999) Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 35:342–350

    Article  CAS  PubMed  Google Scholar 

  29. Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, Kim HT, Morton RA, Kim SJ (2002) Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 62:5365–5369

    CAS  PubMed  Google Scholar 

  30. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 95:15677–15682

    Article  CAS  PubMed  Google Scholar 

  31. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925–5930

    Article  CAS  PubMed  Google Scholar 

  32. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863–870

    CAS  PubMed  Google Scholar 

  33. Labrie F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, Merand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 69:51–84

    Article  CAS  PubMed  Google Scholar 

  34. Lam HY (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiestrase. Biochem Biophys Res Commun 118:27–32

    CAS  PubMed  Google Scholar 

  35. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31

    CAS  PubMed  Google Scholar 

  36. Lau KM, Leav I, Ho SM (1998) Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 139:424–427

    CAS  PubMed  Google Scholar 

  37. Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D (1988) Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 80:1045–1053

    CAS  PubMed  Google Scholar 

  38. Leav I, Merk FB, Kwan PW, Ho SM (1989) Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15:23–40

    CAS  PubMed  Google Scholar 

  39. Love RR, Mazees RB, Barden HS (1992) Effect of tamoxifen on bone mineral density in post menopausal women with breast cancer. N Engl J Med 326:852–856

    CAS  PubMed  Google Scholar 

  40. Lucia MS, Anzano MA, Slatyer MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, Roberts AB, Sporn MB (1995) Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue Ro24–5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 55:5621–5627

    CAS  PubMed  Google Scholar 

  41. McDonald CC, Alexander FE, Whyte BW (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ 311:977–980

    CAS  PubMed  Google Scholar 

  42. Mobbs BG, Johnson IE, Connolly JG, Thompson J (1983) Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: Can estrogen treatment increase androgen receptor content? J Steroid Biochem 19:1279–1290

    CAS  PubMed  Google Scholar 

  43. Mobbs BG, Johnson IE, Liu Y (1990) Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays. Prostate 16:235–244

    CAS  PubMed  Google Scholar 

  44. Montandon F, Williams GM (1994) Comparison of DNA reactivity of poly-phenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68:272–275

    CAS  PubMed  Google Scholar 

  45. Montano MM, Jaiswal AK, Katzenellenbogen BS (1998) Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. J Biol Chem 273:25443–25449

    Article  CAS  PubMed  Google Scholar 

  46. Moore RJ, Gazak JM, Wilson JD (1979) Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17β-estradiol. J Clin Invest 63:351–357

    CAS  PubMed  Google Scholar 

  47. Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53

    Article  CAS  PubMed  Google Scholar 

  48. Neubauer BL, Best KL, Clemens JA, Gates CA, Goode RL, Jones CD, Laughlin ME, Shaar CJ, Toomey RE, Hoover DM (1993) Endocrine and antiprostatic effects of raloxifene (LY 156758) in the male rat. Prostate 23:246–262

    Google Scholar 

  49. O'Brien CA, Liskamp RM, Solomon DH (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462–2465

    PubMed  Google Scholar 

  50. Ofner P, Bosland MC, Vena RL (1992) Differential effects of diethylstilbestrol and estradiol-17 beta in combination with testosterone on rat prostate lobes. Toxicol Appl Pharmacol 112:300–309

    CAS  PubMed  Google Scholar 

  51. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508–1510

    PubMed  Google Scholar 

  52. Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA (1998) Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues. Endocrinol 139:1082–1092

    CAS  PubMed  Google Scholar 

  53. Pollard M (1999) Prevention of prostate-related cancers in Lobund-Wistar rats. Prostate 39:305–309

    Article  CAS  PubMed  Google Scholar 

  54. Price KR, Fenwick GR (1985) Naturally occurring oestrogens in foods-a review. Food Addit Contam 2:73–106

    CAS  PubMed  Google Scholar 

  55. Prins G (1997) Developmental estrogenization of the prostate gland. In: Naz R (ed) Prostate basic and clinical aspects. CRC, New York, pp 247–265

  56. Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, Birch L (1998) Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 139:874–883

    CAS  PubMed  Google Scholar 

  57. Pylkkanen L, Makela S, Valve E, Harkonen P, Toikkanen S, Santti R (1993) Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J Urol 149:1593–1601

    CAS  PubMed  Google Scholar 

  58. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370–1376

    CAS  PubMed  Google Scholar 

  59. Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC (1998) Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21 (waf1/cip1). Prostate 37:51–59

    Article  CAS  PubMed  Google Scholar 

  60. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B (1986) Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76:45–48

    CAS  PubMed  Google Scholar 

  61. Rutquist LE, Johansson H (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645–651

    CAS  PubMed  Google Scholar 

  62. Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H (2000) Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42:45–55

    Article  CAS  PubMed  Google Scholar 

  63. Shughrue PJ, Lane MV, Scrimo PJ, Merchenthaler I (1998) Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 63:498–504

    Article  CAS  PubMed  Google Scholar 

  64. Simard J, Labrie F (1985) Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol 39:141–144

    CAS  PubMed  Google Scholar 

  65. Steiner MS (1993) The role of peptide growth factors in the prostate: a review. Urology 42:99–110

    CAS  PubMed  Google Scholar 

  66. Steiner MS (1995) Review of peptide growth factors in benign prostatic hyperplasia and urologic malignancy. J Urol 153:1085–1096

    CAS  PubMed  Google Scholar 

  67. Steiner MS, Pound CR, Gingrich JR, Patterson AL, Wake RW, Conrad LW, Kisber RH, McSwain M, Shelton T (2002) Acapodene (GTx-006) reduces high grade prostate intraepithelial neoplasia (HGPIN) in phase II clinical trial. Program and abstracts from the American Society of Clinical Oncology 38th Annual Meeting, 18–21 May, Orlando, abstract 719

  68. Treinen KA, Rehm S, Wier PJ (1998) An evaluation of the novel selective estrogen receptor modulator, idoxifene, for effects on reproduction in rats and rabbits. Toxicol Sci 41:199–207

    Article  CAS  PubMed  Google Scholar 

  69. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 11:353–365

    CAS  PubMed  Google Scholar 

  70. Van Leeuwen FE, Benraadt J, Coebergh JWW (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452

    PubMed  Google Scholar 

  71. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534–540

    CAS  PubMed  Google Scholar 

  72. Walsh PC, Wilson JD (1976) The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 57:1093–1097

    CAS  PubMed  Google Scholar 

  73. Wang YZ, Hayward SW, Cao M, Young P, Cunha GR (2001) Role of estrogen signaling in prostatic hormonal carcinogenesis. Program abstracts from the American Urological Association Anaheim 2001 Annual Meeting, 2–7 June, Anaheim, abstract 543

  74. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M (1997) Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 236:140–145

    Article  CAS  PubMed  Google Scholar 

  75. White IN, De Matteis F, Davies A (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F334/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197–2203

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Tennessee, 1211 Union Avenue, Memphis, TN, 38104, USA

    Mitchell S. Steiner & Sharan Raghow

Authors
  1. Mitchell S. Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharan Raghow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell S. Steiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, M.S., Raghow, S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol 21, 31–36 (2003). https://doi.org/10.1007/s00345-002-0316-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-002-0316-x

Keywords

Search

Navigation